| Target Price | $83.13 |
| Price | $72.65 |
| Potential |
14.43%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Mirum Pharmaceuticals Inc 2026 .
The average Mirum Pharmaceuticals Inc target price is $83.13.
This is
14.43%
register free of charge
$99.75
37.30%
register free of charge
$66.66
8.25%
register free of charge
|
|
| A rating was issued by 17 analysts: 16 Analysts recommend Mirum Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Mirum Pharmaceuticals Inc stock has an average upside potential 2026 of
14.43%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 336.89 | 515.92 |
| 80.76% | 53.14% | |
| EBITDA Margin | -18.99% | -3.53% |
| 64.00% | 81.41% | |
| Net Margin | -26.10% | -7.03% |
| 70.23% | 73.07% |
12 Analysts have issued a sales forecast Mirum Pharmaceuticals Inc 2025 . The average Mirum Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Mirum Pharmaceuticals Inc EBITDA forecast 2025. The average Mirum Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Mirum Pharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average Mirum Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.85 | -0.72 |
| 53.75% | 61.08% | |
| P/E | negative | |
| EV/Sales | 7.04 |
12 Analysts have issued a Mirum Pharmaceuticals Inc forecast for earnings per share. The average Mirum Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Mirum Pharmaceuticals Inc...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Sep 24 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Aug 11 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Sep 24 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Aug 11 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


